Medtronic (NYSE:MDT – Get Free Report) issued an update on its FY 2025 earnings guidance on Saturday morning. The company provided earnings per share (EPS) guidance of 5.400-5.500 for the period, compared to the consensus estimate of 5.440. The company issued revenue guidance of $33.1 billion-$33.6 billion, compared to the consensus revenue estimate of $33.4 billion.
Medtronic Trading Down 0.2 %
Shares of MDT stock opened at $77.95 on Monday. Medtronic has a 12-month low of $68.84 and a 12-month high of $91.00. The company has a market capitalization of $99.95 billion, a P/E ratio of 28.35, a P/E/G ratio of 2.27 and a beta of 0.82. The company has a quick ratio of 1.55, a current ratio of 2.03 and a debt-to-equity ratio of 0.47. The firm has a 50-day moving average price of $81.20 and a 200 day moving average price of $83.19.
Medtronic (NYSE:MDT – Get Free Report) last announced its earnings results on Thursday, May 23rd. The medical technology company reported $1.46 earnings per share for the quarter, topping analysts’ consensus estimates of $1.45 by $0.01. Medtronic had a net margin of 11.36% and a return on equity of 13.47%. The company had revenue of $8.59 billion during the quarter, compared to the consensus estimate of $8.44 billion. During the same period in the previous year, the firm posted $1.57 earnings per share. The company’s revenue was up .5% on a year-over-year basis. Research analysts forecast that Medtronic will post 5.44 earnings per share for the current fiscal year.
Medtronic Increases Dividend
Wall Street Analyst Weigh In
MDT has been the subject of several analyst reports. UBS Group lifted their price target on shares of Medtronic from $75.00 to $76.00 and gave the stock a sell rating in a research report on Friday, May 24th. Truist Financial reduced their price target on shares of Medtronic from $90.00 to $88.00 and set a hold rating for the company in a report on Friday, May 24th. Needham & Company LLC reiterated a hold rating on shares of Medtronic in a report on Friday, May 24th. The Goldman Sachs Group started coverage on shares of Medtronic in a report on Thursday, May 30th. They issued a sell rating and a $83.00 price target for the company. Finally, Royal Bank of Canada reiterated a sector perform rating and issued a $92.00 price target on shares of Medtronic in a report on Wednesday, June 5th. Two research analysts have rated the stock with a sell rating, six have issued a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of Hold and a consensus price target of $91.09.
Read Our Latest Stock Report on MDT
Insider Transactions at Medtronic
In other Medtronic news, CEO Geoffrey Martha sold 19,113 shares of the company’s stock in a transaction on Friday, June 7th. The shares were sold at an average price of $83.77, for a total transaction of $1,601,096.01. Following the sale, the chief executive officer now directly owns 143,348 shares of the company’s stock, valued at $12,008,261.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.30% of the stock is currently owned by insiders.
Medtronic Company Profile
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.
Featured Stories
- Five stocks we like better than Medtronic
- Why is the Ex-Dividend Date Significant to Investors?
- Positive News is Driving This Cancer Drug Maker’s Stock Higher
- How to Capture the Benefits of Dividend Increases
- Top 3 Defense Stocks That Should Be on Your Radar
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- Why This Banking Stock Might Be Nearing the Bottom of Its Cycle
Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.